Want to see JP:4575 full AI Analyst Report?
CanBas Co., Ltd. (4575) AI Stock Analysis
CanBas Co., Ltd.
(TSE/TYO:4575)
The overall score is heavily weighed down by the company's fundamental financial risks as a pre-revenue biotech. While technical indicators show a relatively strong medium-term uptrend with the price remaining above major moving averages, the complete lack of fundamental cash generation, negative valuation metrics, and the high likelihood of near-term equity dilution to fund operations remain the primary constraints.
CanBas Co., Ltd. (4575) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 14.76B
- Dividend Yield
- ―
- Average Volume (3M)
- 177.56K
- Price to Earnings (P/E)
- -11.3
- Beta (1Y)
- 0.83
- Revenue Growth
- ―
- EPS Growth
- -8.52%
- Country
- Japan
- Employees
- 18
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
CanBas Co., Ltd. Business Overview & Revenue Model
Company Description
CanBas Co., Ltd. is a biopharmaceutical company in the clinical stage, dedicated to discovering and developing new therapies for cancer patients. Its main investigational compounds include CBP501, a calmodulin-modulating peptide aimed at treating var...
CanBas Co., Ltd. Financial Statement Overview
Summary
Financials reflect a pre-revenue profile with severe cash burn and zero top-line generation. While a completely debt-free balance sheet provides initial stability, the rapidly depleting equity base and widening net losses necessitate imminent external funding.
Income Statement
15Very NegativeBalance Sheet
75PositiveCash Flow
15Very Negative| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | -820.00M | -984.00M | -671.00M | -608.00M |
| EBITDA | -1.35B | -1.36B | -47.67M | 53.65M | -1.24B | -848.65M |
| Net Income | -1.31B | -1.31B | -1.16B | -1.21B | -1.24B | -855.58M |
Balance Sheet | ||||||
| Total Assets | 1.78B | 1.78B | 3.05B | 2.43B | 2.09B | 790.71M |
| Cash, Cash Equivalents and Short-Term Investments | 1.45B | 1.45B | 2.83B | 1.89B | 1.62B | 737.77M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 367.34M |
| Total Liabilities | 134.71M | 134.71M | 107.00M | 91.99M | 153.85M | 540.02M |
| Stockholders Equity | 1.64B | 1.64B | 2.94B | 2.34B | 1.93B | 250.69M |
Cash Flow | ||||||
| Free Cash Flow | 0 | -1.42B | -771.45M | -1.28B | -1.40B | -719.81M |
| Operating Cash Flow | 0 | -1.42B | -771.45M | -1.28B | -1.40B | -719.81M |
| Investing Cash Flow | 0 | 0 | 122.00K | 0 | 0 | 182.00K |
| Financing Cash Flow | 0 | 0 | 1.75B | 1.54B | 2.27B | 282.75M |
CanBas Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4575, the sentiment is Negative. The current price of 728.00 is below the 20-day moving average (MA) of 756.65, below the 50-day MA of 770.88, and below the 200-day MA of 743.42, indicating a neutral trend. The MACD of -3.17 indicates Negative momentum. The RSI at 48.92 is Neutral, neither overbought nor oversold. The STOCH value of 69.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4575.
CanBas Co., Ltd. Peers Comparison
Overall Rating
JP:459348Neutral- JP:457547Neutral
JP:497845Neutral
JP:777442Neutral
JP:459938Underperform
JP:777637Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| JP:4593 | 48Neutral | JPY 37.00B | 55.04 | ― | ― | -47.32% | ― |
| JP:4575 | 47Neutral | JPY 14.81B | -11.28 | ― | ― | ― | -8.52% |
| JP:4978 | 45Neutral | JPY 13.03B | -26.58 | ― | ― | -18.71% | -246.54% |
| JP:7774 | 42Neutral | JPY 25.54B | -58.02 | ― | ― | 3.43% | -53.59% |
| JP:4599 | 38Underperform | JPY 8.71B | -4.68 | ― | ― | ― | 4.85% |
| JP:7776 | 37Underperform | JPY 7.43B | -6.49 | ― | ― | -56.16% | 3.12% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4575 | CanBas Co., Ltd. | 749.00 | -54.00 | -6.72% | |
| JP:4593 | Healios KK | 273.00 | -221.00 | -44.74% | |
| JP:4599 | StemRIM Inc. | 139.00 | -134.00 | -49.08% | |
| JP:4978 | ReproCELL Inc. | 122.00 | -51.00 | -29.48% | |
| JP:7774 | Japan Tissue Engineering Co., Ltd. | 629.00 | 153.00 | 32.14% | |
| JP:7776 | CellSeed Inc. | 188.00 | -249.00 | -56.98% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 01, 2026